Abstract:Introduction: The aim was to investigate the risk factors for recurrence after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC) and to provide a basis for clinical prevention of recurrence of NMIBC. Methods: From January 2012 to December 2020, 592 patients with NMIBC who underwent TURBT attending the Second Affiliated Hospital of Xi’an Jiaotong University were retrospectively included in this study. Patients were divided into relapse and relapse-free groups according to whether relapse occurred within 2 years. Ultimately, 72 patients were included in the relapse group and 350 patients were included in the relapse-free group. Observation indicators included age, sex, smoking, underlying disease (hypertension, diabetes, coronary heart disease), two or more lesions, tumor size, hematuria, pathology grading (low, medium, high), staging (Ta, T1), muscular invasion in initial pathology, tumor base (sessile, pedunculated), use of intravesical drug (pirarubicin, bacillus Calmette-Guerin [BCG], mitomycin, hydroxycamptothecin, gemcitabine). Results: In this study, the 2-year recurrence rate of NMIBC patients after TURBT was 17.06%. There were significant differences in comparison of pirarubicin, BCG, and mitomycin treatment between the two groups ( p < 0.05). To avoid missing risk factors for recurrence, factors with p < 0.1 were analyzed. The results of univariate logistic regression analysis showed that NMIBC patients with BCG treatment (OR = 5.088, 95% CI = 1.444–17.73, p = 0.012), high pathology grading (OR = 0.415, 95% CI = 0.197–0.880, p = 0.023), T1 stage (OR = 2.097, 95% CI = 0.996–4.618, p = 0.059), mitomycin treatment (OR = 5.029, 95% CI = 1.149–21.77, p = 0.031), and pirarubicin treatment (OR = 1.794, 95% CI = 1.079–3.030, p = 0.024) had significantly higher risk of recurrence within 2 years after TURBT. The results of multivariate logistic regression analysis showed that NMIBC patients with high pathology grading (OR = 0.4030, 95% CI = 0.1702–0.8426, p = 0.0241), pirarubicin treatment (OR = 1.961, 95% CI = 1.159–3.348, p = 0.0125), and BCG treatment (OR = 6.201, 95% CI = 1.275–29.73, p = 0.0190) had significantly higher risk of recurrence within 2 years after TURBT. Conclusion: Our study highlights the importance of postoperative surveillance and individualized treatment for patients with NMIBC. Our findings show that high pathology grading, pirarubicin treatment, and BCG treatment are independent risk factors for recurrence after TURBT in patients with NMIBC. However, caution is warranted when interpreting our findings due to the small sample size and the need for further research to confirm the negative impact of mitomycin and BCG on recurrence rates.

Smoking behavior and the risks of tumor recurrence and progression in patients with non‐muscle‐invasive bladder cancer

Impact of smoking intensity on outcomes of patients with non muscle invasive bladder cancer treated by BCG immunotherapy

Effect of smoking on the recurrence and progression of non-muscle-invasive bladder cancer

The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

Exploring the risk factors of recurrence and progression in 188 patients with non-muscle invasive bladder cancer by retrospectively analysis

Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions

Body mass index and waist circumference in relation to risk of recurrence and progression after non‐muscle invasive bladder cancer

New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer

Re: Factors Affecting Recurrence and Progression of High Grade Non Invasive Bladder Cancer Treated by Intravesical BCG.

Smoking-related epigenetic modifications are associated with the prognosis and chemotherapeutics of patients with bladder cancer

Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort

RNA-seq analysis of non-muscular invasive bladder cancer to reveal different gene expression profiles between smoking and non-smoking patients.

Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens

Smoking Behavior and Prognosis After Colorectal Cancer Diagnosis: A Pooled Analysis of 11 Studies

Assessing the predictive value of smoking history for immunotherapy outcomes in bladder cancer patients

The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes

Advances in relationship between smoking and bladder cancer

Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose-effect relationship

Smoking Status and Survival Among a National Cohort of Lung and Colorectal Cancer Patients

Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype